Powerful paper Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) congratulations nature.com/articles/s4158…

🎧 How can MSIntuit® CRC empower pathologists to optimize MSI testing for colorectal cancer with H&E slides? Hear our Lead Data Scientist Rémy Dubois explain our poster at #USCAP24. Catch the poster presentation on Wednesday, March 27 at 1:00pm - 4:30pm EDT at the Baltimore

Introducing TLS Detect RUO – an AI research tool designed to detect the presence of tertiary lymphoid structures (TLS) across various tumor types using digital H&E slides. TLS is a novel biomarker for assessing survival risk and immunotherapy response in untreated cancer

New intelligence to understand biology is needed. Because it is just too complex for human to handle! Follow Owkin and the news to come #genai #futureofbiotech

TLS detect ruo from Owkin . Light up or light down to understand primary response to #immuno therapy!

AI has the potential to change drug discovery. Here’s what it will take Thomas Clozel Owkin #FCImpactCouncil f-st.co/1jJt7Dj

AI has the potential to change drug discovery. Here’s what it will take Thomas Clozel Owkin #FCImpactCouncil f-st.co/YqCFtu0

📣 Building on Phikon’s success (huggingface.co/owkin/phikon), our #foundationmodel, Phikon-v2, is now publicly available on Hugging Face! Using state-of-the-art self-supervised learning methods, we pre-trained a large vision transformer on 460 million unlabeled histology images

The idea that the most ardent AI proponents pinning hopes on AGI (vs utility of intermediate steps) may also be playing out in techbio; struck by recent piece by Owkin founder Thomas Clozel explicitly citing "need to build scientific AGI" fastcompany.com/91190444/how-t… Isaac Kohane

📰 Check out Mosaic research in this month’s issue of Pharmaceutiques Magazine! Spatial omics technologies are poised to deliver major scientific breakthroughs in the next few years, connecting the different cell types that coexist in the tumor microenvironment and bringing a

“L’intelligence artificielle est une façon d'accélérer la médecine et de donner des super-pouvoirs aux médecins. Mais il n’y a pas que l’IA, il y a des process à mettre en place dans les hôpitaux.” Les explications du médecin Thomas Clozel dans #CàVous ⬇️

“La santé doit être gérée par des gens qui font des start-ups et pas par des ministres.” L’intelligence artificielle au service de la santé : Thomas Clozel, médecin et PDG d’Owkin, explique sa vision dans #CàVous

L'IA va-t-elle tuer des emplois ou sauver des vies ? Thomas Clozel est un médecin qui aime la tech et qui assume qu'on ne comprend encore presque rien en biologie et en médecine... mais que l'IA peut certainement nous aider : gdiy.fr/business/thoma…

As we head into Mosaic research's second year, we reflect on the ground we've covered. From selecting the right partners and technologies to ensuring seamless coordination across multiple hospitals and disciplines, we’ve gained invaluable insights into managing large-scale,

The future of healthcare is hybrid: tech and human care working together Thomas Clozel Owkin #FCImpactCouncil f-st.co/mkwmpfX

Towards #singularity in #medicine Fast Co. Tech Fast Company - doctors need to be copiloted but also, sometimes, replaced by agents🤖 #agi fastcompany.com/91233495/a-vis…

🔬Pour finir, j’ai rencontré Thomas Clozel, le fondateur de Owkin, une startup spécialisée dans l’IA appliquée à la recherche médicale. L’entreprise propose de former des modèles d’IA au service de la découverte de médicaments, des diagnostics, du développement de la

Can AI help Pharma speed up drug development? The Wall Street Journal features our CEO Thomas Clozel alongside Aviv Regev from Genentech, AstraZeneca's Chief Data Scientist Jim Weatherall, and GSK's Senior Director of Machine Learning and AI Patrick Schwab. And Le Figaro reports on the first patient

Owkin at the Ritz Paris 🤩 Thomas Clozel, Maria Teleńczuk and myself (sorry Thomas, we missed the opportunity to do a selfie with you 🙊) had the immense pleasure of being invited by Anthropic (thank you Sarah Heck!) for a cocktail reception following the #AIActionSummit2025 🇫🇷

AI is transforming medicine and Dr. Thomas Clozel is leading the charge. A former hematologist turned AI pioneer, he founded Owkin in 2016 to revolutionize drug discovery and diagnostics. The result? A global leader in AI-powered biotech with a mission to make healthcare